XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.25.2

Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($) | 3 Months Ended | 6 Months Ended |
--- | --- | --- | ---
Jun. 30, 2025 | Dec. 31, 2024 | Sep. 30, 2024 | Jun. 30, 2024 | Dec. 31, 2022 | Sep. 30, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Jun. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2017 | Jun. 30, 2017 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Jun. 30, 2015 | Jun. 30, 2025 | Jun. 30, 2024 | Oct. 31, 2021
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue | $ 22,263,000 |  |  | $ 10,971,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,034,000 | $ 18,150,000 |
Milestone revenue recognition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Cash is generally received within 30 days of milestone achievement |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | IND clearance from the FDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000.0 |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 2 clinical trial initiation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | First BLA approval - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | First MAA approval - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | First BLA approval - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000.0 |  |
GSK | PD-1 (Jemperli/Dostarlimab) | First MAA approval - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |
GSK | PD-1 (Jemperli/Dostarlimab) | First commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Second commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Third commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000.0 |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Fourth commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000.0 |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Milestones recognized through June 30, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 133,000,000.0 |  |
GSK | PD-1 (Jemperli/Dostarlimab) | Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 140,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | IND clearance from the FDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000.0 |  |  |  |  |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Phase 2 clinical trial initiation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Phase 3 clinical trial initiation - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Phase 3 clinical trial initiation - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first BLA - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first MAA - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first BLA - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | First BLA approval - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | First MAA approval - first indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | First BLA approval - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first MAA - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | First MAA approval - second indication |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | First commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Second commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Third commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Fourth commercial sales milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Milestones recognized through June 30, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,000,000.0 |  |
GSK | TIM-3 (GSK4069889/Cobolimab) | Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 260,000,000.0 |  |
Sagard | JEMPERLI Royalty Monetization Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rights retained |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 75,000,000
Royalties agreement, maximum annual royalty payout capacity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000,000
Vanda | Milestones recognized through June 30, 2025 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35,000,000.0 |  |
Vanda | FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |
Vanda | Regulatory approval for marketing of the first licensed product in the EU |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000.0 |  |
Vanda | Commercial sales first exceed $100.0 million |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones that may be recognized in the future |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000.0 |  |
Commercial sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000.0 |  |

X
- Definition Advance Future Royalties, Annual Sales Threshold + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesAnnualSalesThreshold
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Advance Future Royalties, Retained Rights After Annual Sales Threshold Exceeded + References No definition available. + Details
Name: | anab_AdvanceFutureRoyaltiesRetainedRightsAfterAnnualSalesThresholdExceeded
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Net Sales Royalty Threshold + References No definition available. + Details
Name: | anab_NetSalesRoyaltyThreshold
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Contingent + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodContingent
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of effect, from relationship that timing of satisfaction of performance obligation has on timing of payment, on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time and on obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 + Details
Name: | us-gaap_ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1JemperliDostarlimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FilingOfBiologicsLicenseApplicationFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FilingOfMMAFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FilingOfBiologicsLicenseApplicationSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FirstBiologicsLicenseApplicationApprovalDMMRECMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FirstMarketingAuthorizationApplicationApprovalFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FirstBiologicsLicenseApplicationApprovalSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FilingOfMMASecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FirstMarketingAuthorizationApplicationApprovalSecondIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FirstCommercialSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_SecondCommercialSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_ThirdCommercialSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FourthCommercialSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_CumulativeMilestonesRecognizedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_MilestonesYetToBeRecognizedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anab_SagardHealthcareRoyaltyPartnersLPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_JEMPERLIRoyaltyMonetizationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anab_VandaPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FDARegulatoryApprovalForMarketingOfFirstLicensedProductInTheUSAForTheTreatmentOfActiveFlaresInGPPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_RegulatoryApprovalForMarketingOfTheFirstLicensedProductInTheEUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_CommercialSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |